HNSBF Stock Chart & Stats
$2.90
$0.00(0.00%)
At close: 4:00 PM EDT
$2.90
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.73 - $4.58
Previous CloseN/A
Volume8.00K
Average Volume (3M)958.00
Market Cap
$390.66M
Enterprise Value$4.01K
Total Cash (Recent Filing)$552.81M
Total Debt (Recent Filing)$1.03B
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 05, 2026EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume0
30 Day Avg. Volume958
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.60Price Target Upside265.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$45.85M
Bulls Say, Bears Say
Bulls Say
Robust Phase III / Confirmatory Clinical DataLarge, statistically significant eGFR gains and positive PAES topline materially raise the probability of full regulatory approvals and durable clinical adoption in transplant centers. Strong confirmatory efficacy supports long-term prescribing, payer engagement, and an enlarged addressable market for imlifidase.
Material Out‑licensing Cash InflowThe EUR 110M upfront meaningfully strengthens liquidity and extends runway ahead of a U.S. PDUFA and commercial launch. A stronger balance sheet reduces near-term refinancing pressure and funds launch, regulatory work, and site readiness—durable support for execution through approval milestones.
Healthy Product Margins And Improving Sales MomentumHigh product-level gross margins (~60%) and clear QoQ sales growth in core EU markets indicate attractive unit economics and improving commercial traction. If sustained, margins support path to profitability as volumes scale and reimbursement solidifies across transplant centers.
Bears Say
Negative Equity And High LeverageNegative equity combined with ~1.03B total debt creates structural leverage and solvency risk, limiting strategic flexibility. Delays in approvals or slower adoption could force dilutive financings or covenant concessions, impeding long-term commercialization and R&D plans.
Sustained Cash BurnPersistent negative operating cash flow and free cash flow indicate reliance on external funding absent a rapid revenue ramp. Even with the upfront, continued burn raises dilution and execution risk over the next 2–6 months if U.S. approval or commercial uptake lags expectations.
Weak Top-line Scale And Large LossesA steep TTM revenue decline and very wide net losses show limited current commercial scale and high operating leverage. Rising SG&A for U.S. launch further widens losses, so long-term profitability hinges on successful U.S. adoption and EU approval conversions—execution-sensitive risks.
HNSBF FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was $2.73 and its highest was $4.58 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is $390.66M.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 98 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -$0.263 earnings per share for the quarter, missing the consensus estimate of -$0.035 by -$0.229.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 0.59.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -$0.263 in its last earnings report, missing expectations of -$0.035. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in HNSBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
HNSBF Stock 12 Month Forecast
Average Price Target
$10.60
▲(265.44% Upside)
Ownership Overview
―
Insiders
1.16% Mutual Funds
― Other Institutional Investors
98.64% Public Companies and
Individual Investors